top of page

Structured Product Labeling Services for Accurate FDA Compliance

Axentra provides industry-leading structured product labeling services to ensure your drug listings meet FDA standards. With a focus on compliance and accuracy, our services encompass end-to-end lifecycle management, from NDC creation to post-market oversight. Trust Axentra to deliver reliable solutions, keeping your products FDA-compliant and ready for market. Choose us for unparalleled expertise in structured product labeling services.

Complete Drug Listing & SPL Lifecycle Management

Axentra manages every stage of FDA Drug Listing for prescription, OTC, API, and repackaged drug products—ensuring accurate, compliant, and fully validated SPL submissions. We design correct NDC structures, maintain labeler code integrity, prepare initial listings, and manage all required updates for formulation changes, labeling revisions, package alterations, commercial status changes, and annual certifications. Each SPL is validated for structure, terminology, and content to meet FDA’s electronic submission standards and avoid the errors that often lead to misbranding citations or import holds.

NDC Creation, Updates & Lifecycle Management

Axentra manages every stage of FDA Drug Listing for prescription, OTC, API, and repackaged drug products—ensuring accurate, compliant, and fully validated SPL submissions. We design correct NDC structures, maintain labeler code integrity, prepare initial listings, and manage all required updates for formulation changes, labeling revisions, package alterations, commercial status changes, and annual certifications. Each SPL is validated for structure, terminology, and content to meet FDA’s electronic submission standards and avoid the errors that often lead to misbranding citations or import holds.

NDC Strategy, Labeler Code Management & Compliance Accuracy

Foreign manufacturers frequently struggle with the technical rules behind NDC assignment, labeler code utilization, and the alignment of establishment data with marketed product details. Axentra eliminates this risk by managing NDC planning, preventing code collisions, ensuring correct packager associations, and aligning every SPL with the facility’s Establishment Registration and FEI data. Our expertise extends to correcting legacy listings, resolving inactive or rejected SPLs, and ensuring your products appear accurately in FDA’s NDC Directory and Drug Listing database at all times.

Inspection-Ready Labeling Compliance & Post-Market Oversight

Beyond SPL creation, Axentra ensures your drug listings fully support FDA inspection expectations by aligning SPL text with your approved labeling, promotional claims, and change-control documentation. We proactively monitor FDA guidance, labeling updates, therapeutic class requirements, and electronic submission standards to determine when your listings require revision. Our integrated approach links SPL compliance with facility registration, labeling compliance, and import readiness—providing continuous oversight and reducing regulatory and operational risk across the product lifecycle.

Why Choose Axentra for Drug Listing & SPL Compliance

Expert NDC & Labeler Code Management That Prevents Costly Errors

We design correct NDC structures, maintain labeler code integrity, and prevent code conflicts or misalignments—reducing the risk of listing rejection, import delays, or database inconsistencies.

Fully Validated, FDA-Compliant SPL Submissions Across the Entire Product Lifecycle

Every SPL is technically validated for structure, terminology, dosage form coding, packager association, and regulatory category—ensuring your listings meet FDA’s strict electronic submission standards and remain accurate through all formulation, label, and packaging updates.

Integrated Oversight Connecting SPL, Registration, Labeling & Post-Market Compliance

Axentra links your SPL filings with establishment registration, labeling compliance, and change-control requirements—creating a unified, inspection-ready system that minimizes regulatory risk and keeps your products visible and compliant in FDA’s Drug Listing database.

Drug Listing and SPL submission   — Frequently Asked Questions

What is SPL and why does FDA require it?

SPL is the FDA's required XML format for submitting drug listing and labeling information electronically. Every drug listing and update must be filed as a validated SPL.

When must drug registration information be reviewed and updated?

Annually. 21 CFR 207.29 requires that "subsequent reviews and updates must occur annually, during the period beginning on October 1 and ending December 31 of each calendar year". Note this is a yearly review and update cycle, which is different from the biennial renewal that applies to food facilities.

How do I get an NDC labeler code?

The labeler code is the first segment of the National Drug Code and is requested from FDA as part of establishment registration and drug listing. Axentra requests the labeler code, then builds the product and package segments for each SKU and submits the listing in SPL.

bottom of page

Drug listing & SPL

Structured Product Labeling Services for Accurate FDA Compliance

NDC structure, validated SPL, and listings that stay current after every label or product change.

Facility registration identifies the site. Drug listing identifies each product. An NDC or a Directory listing is not FDA approval of the product. Unlisted drugs cannot be legally marketed.

What Axentra lists

Axentra manages FDA drug listing for prescription, OTC, API, and repackaged drug products — from labeler code through required updates.

NDC and labeler code

FDA assigns the labeler-code segment. Axentra requests that code, then builds the product and package segments for each SKU.

Initial listing in SPL

Every listing and update is filed as a validated SPL so structure, terminology, and content meet FDA’s electronic standards.

Required updates

Formulation, labeling, package, and commercial-status changes are filed when they occur — not left until the next certification.

June and December review

Under 21 CFR 207.57, listing information is reviewed and updated in June and December. Unchanged listings can be certified in the October–December registration window.

Listing is not registration

Foreign drug establishments whose drugs are imported into the United States must register, list each drug intended for commercial distribution, and designate a U.S. Agent. Registration alone does not satisfy listing or SPL. Listing work is quoted separately from the $299 Market Access Bundle.

  • Establishment registration identifies the manufacturing, packaging, or labeling site
  • Drug listing identifies each product with an NDC and an SPL file
  • SPL text must match the labeled claims and change-control record
  • A listing left uncertified can be marked inactive

What must stay aligned

  • NDC structure and labeler-code integrity — collisions and wrong packager associations cause Directory errors.
  • FEI and establishment data on the listing must match the registered facility.
  • Labeling revisions and package changes require a new SPL, not a silent edit.
  • Drug establishment registration is reviewed every year from October 1 to December 31 (21 CFR 207.29).

Frequently asked questions

What is SPL and why does FDA require it?

SPL is the FDA’s required XML format for submitting drug listing and labeling information electronically. Every drug listing and update must be filed as a validated SPL.

What is an NDC (National Drug Code)?

The National Drug Code is FDA’s unique three-segment identifier for a drug product. FDA assigns the labeler-code segment; the labeler assigns the product and package segments and submits the full NDC through the drug listing process. An NDC or a Directory listing is not FDA approval of the product.

How do I get an NDC labeler code?

The labeler code is the first segment of the National Drug Code. FDA assigns it after you submit an NDC Labeler Code Request — a distinct SPL step alongside establishment registration and drug listing. Axentra requests the labeler code, then builds the product and package segments for each SKU.

How often must drug listings be updated and certified?

Update listing information whenever material product data changes. Under 21 CFR 207.57, registrants review and update listing information in June and December. If nothing has changed, a “no changes” certification may be filed during the annual establishment registration window (October 1 – December 31). A listing left uncertified can be marked inactive.

Do foreign drug manufacturers need drug listing?

Yes. Foreign drug establishments whose drugs are imported or offered for import into the United States must register with FDA, list each drug intended for commercial distribution (submitted as SPL with an NDC), and designate a U.S. Agent. Registration and listing are not FDA product approval.

Does facility registration cover drug listing and SPL?

No. Facility registration identifies the site. Drug listing identifies each product via an NDC and an SPL file. You generally need both before commercial distribution.

Talk to Axentra

Email info@axentracompliance.com · US clients: call +1 505 358 4858

Contact Axentra